Postes actifs de Michael Tolpa
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| TRANSLATE BIO, INC. | Treasurer | - | - |
| PROVENTION BIO, INC. | Treasurer | 27/04/2023 | - |
| Directeur/Membre du Conseil | - | 27/04/2023 | |
| President | - | 27/04/2023 |
Historique de carrière de Michael Tolpa
Statistiques
Internationale
| Etats-Unis | 3 |
Opérationnelle
| Treasurer | 2 |
| Director/Board Member | 1 |
| President | 1 |
Sectorielle
| Health Technology | 3 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Entreprise privées | 2 |
|---|---|
Translate Bio, Inc.
 Translate Bio, Inc. BiotechnologyHealth Technology Translate Bio, Inc. engages in the research and development of therapeutic drugs. It focuses on developing medicines to treat diseases caused by protein or gene dysfunction. Its lead product candidate, MRT5005 is designed for the treatment of cystic fibrosis. The company was founded by Arthur M. Krieg and Jeannie T. Lee in 2011 and is headquartered in Lexington, MA. | Health Technology |
Provention Bio, Inc.
 Provention Bio, Inc. Pharmaceuticals: MajorHealth Technology Provention Bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapeutics and solutions. Its products include PRV-031 for the interception of type 1 diabetes (T1D), PRV-015 for the treatment of gluten-free diet non-responding celiac disease, PRV-6527 for Crohn’s disease, PRV-3279 for the treatment of lupus, and PRV-101 for the prevention of acute coxsackie virus B (CVB), and the prevention of type 1 diabetes (T1D) onset. The company was founded by Francisco Leon and Ashleigh Palmer on October 4, 2016 and is headquartered in Red Bank, NJ. | Health Technology |
- Bourse
- Insiders
- Michael Tolpa
- Expérience
